Literature DB >> 24519760

Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis.

Zhang Yongtao1, Wang Kunzheng, Zheng Jingjing, Shan Hu, Kou Jianqiang, Liu Ruiyu, Wang Chunsheng.   

Abstract

Bone metabolism disorder has been identified to play a vital role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). The local renin-angiotensin system (RAS) in bone is newly defined to be closely related to the bone metabolism. However, it is unknown whether the local RAS is involved in GIOP. Adult male New Zealand white rabbits were treated with saline, dexamethasone (DXM) alone, or DXM combined with perindopril. The expression of main RAS components in trabecular bone was examined at mRNA and/or protein levels. Bone metabolism was analyzed using dual-energy X-ray absorptiometry, histomorphometry, biomechanics, biochemical techniques, and quantitative RT-PCR. The expressions of local bone angiotensin II, angiotensin types 1 and 2 receptors, and angiotensin-converting enzyme at mRNA and/or protein levels increased when DXM-induced osteoporosis was present. Whereas, perindopril significantly blocked the activation of the local RAS and partially reversed GIOP. Mineralizing surface, mineral apposition rate, and bone formation rate were decreased by DXM, along with serum osteocalcin being downregulated. These changes were then reversed by the use of perindopril. Osteoclast number, osteoclast surface, and eroded surface increased after the administration of DXM, and urinary deoxypyridinoline was upregulated. These were also inhibited when perindopril was given. Quantitative RT-PCR using RNA isolated from the lumbar vertebrae revealed an increase in the SOST expression and a decrease in the Runx2 expression, whereas the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio and the expression of tartrate resistant acid phosphatase were increased, which were all inhibited by perindopril. The results of this study provide evidence for the role of local RAS is involved in GIOP, and GIOP may be ameliorated by blocking the activation of local RAS in the bone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519760     DOI: 10.1007/s12020-014-0196-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

1.  Regulation of the expression of the rat angiotensin II receptor mRNA.

Authors:  N Iwai; T Inagami
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

Review 2.  Sclerostin: a gem from the genome leads to bone-building antibodies.

Authors:  Chris Paszty; Charles H Turner; Martyn K Robinson
Journal:  J Bone Miner Res       Date:  2010-09       Impact factor: 6.741

Review 3.  Fluid shifts due to microgravity and their effects on bone: a review of current knowledge.

Authors:  Ian D McCarthy
Journal:  Ann Biomed Eng       Date:  2005-01       Impact factor: 3.934

4.  Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells.

Authors:  H Hagiwara; Y Hiruma; A Inoue; A Yamaguchi; S Hirose
Journal:  J Endocrinol       Date:  1998-03       Impact factor: 4.286

Review 5.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

6.  Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

Authors:  R Hatton; M Stimpel; T J Chambers
Journal:  J Endocrinol       Date:  1997-01       Impact factor: 4.286

Review 7.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 8.  Basic biomechanical measurements of bone: a tutorial.

Authors:  C H Turner; D B Burr
Journal:  Bone       Date:  1993 Jul-Aug       Impact factor: 4.398

9.  Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension.

Authors:  A Sato; H Suzuki; Y Nakazato; H Shibata; T Inagami; T Saruta
Journal:  J Hypertens       Date:  1994-05       Impact factor: 4.844

10.  Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats.

Authors:  I Hamming; H van Goor; A J Turner; C A Rushworth; A A Michaud; P Corvol; G Navis
Journal:  Exp Physiol       Date:  2008-01-11       Impact factor: 2.969

View more
  21 in total

1.  Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.

Authors:  Yong Li; Guang-Si Shen; Chen Yu; Guang-Fei Li; Jun-Kang Shen; You-Jia Xu; Jian-Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients.

Authors:  B Shuai; Y P Yang; L Shen; R Zhu; X J Xu; C Ma; L Lv; J Zhao; J H Rong
Journal:  Osteoporos Int       Date:  2014-12-17       Impact factor: 4.507

3.  Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Authors:  Allison L Kuipers; Candace M Kammerer; J Howard Pratt; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Joseph M Zmuda
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

4.  Genistein attenuates glucocorticoid-induced bone deleterious effects through regulation Eph/ephrin expression in aged mice.

Authors:  Yuan Cheng; Wei-Lin Wang; Jun-Jun Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Icariin attenuates glucocorticoid-induced bone deteriorations, hypocalcemia and hypercalciuria in mice.

Authors:  Jing Zhang; Jia Song; Jiang Shao
Journal:  Int J Clin Exp Med       Date:  2015-05-15

6.  Captopril, an angiotensin-converting enzyme inhibitor, possesses chondroprotective efficacy in a rat model of osteoarthritis through suppression local renin-angiotensin system.

Authors:  Yang Tang; Xiaopeng Hu; Xiongwei Lu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 7.  Rabbit as model for osteoporosis research.

Authors:  María Permuy; Mónica López-Peña; Fernando Muñoz; Antonio González-Cantalapiedra
Journal:  J Bone Miner Metab       Date:  2019-05-13       Impact factor: 2.626

8.  Icariin ameliorates dexamethasone‑induced bone deterioration in an experimental mouse model via activation of microRNA‑186 inhibition of cathepsin K.

Authors:  Yongsheng Ma; Hao Yang; Junqing Huang
Journal:  Mol Med Rep       Date:  2017-11-15       Impact factor: 2.952

9.  The Embryonic Chick Femur Organotypic Model as a Tool to Analyze the Angiotensin II Axis on Bone Tissue.

Authors:  Thais Francini Garbieri; Victor Martin; Carlos Ferreira Santos; Pedro de Sousa Gomes; Maria Helena Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

10.  Effects of the Local Bone Renin-Angiotensin System on Titanium-Particle-Induced Periprosthetic Osteolysis.

Authors:  Zhiping Zhao; Changyao Wang; Yingxing Xu; Xiangyu Wang; Bin Jia; Tengbo Yu; Yingzhen Wang; Yongtao Zhang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.